Drug firm Cadila Healthcare on Thursday said the first batch of 30,000 COVID Kavach Elisa tests manufactured by its arm Zydus Diagnostics have been supplied to Indian Council of Medical Research (ICMR), free of cost.
These test kits have been manufactured in technology transfer with ICMR-NIV of Pune for surveillance purposes, Cadila Healthcare said in a filing to BSE.
Earlier, the company had partnered with ICMR to be better equipped against infectious disease outbreaks, and help people, who are at high risk, particularly in distant, remote areas of the country, the filing said.
The company has been manufacturing and marketing a range of Elisa kits for detection and surveillance of rare and neglected diseases in humans and livestock, it added.
Shares of Cadila Healthcare were trading at Rs344per scrip on BSE, up 1.91 per cent from its previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app